Efficacy News and Research

RSS
ARIAD provides update on corporate developments, reports Q1 2014 financial results

ARIAD provides update on corporate developments, reports Q1 2014 financial results

Air, surface sampling techniques used by US government effective in fighting bioterrorism, says study

Air, surface sampling techniques used by US government effective in fighting bioterrorism, says study

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

New research focuses on using wheat fiber to lower cholesterol and prevent development of heart disease

New research focuses on using wheat fiber to lower cholesterol and prevent development of heart disease

New expert guidance encourages healthcare institutions to implement prevention efforts infectious diarrhea

New expert guidance encourages healthcare institutions to implement prevention efforts infectious diarrhea

AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

Naurex's two lead antidepressant programs achieve major milestones

Naurex's two lead antidepressant programs achieve major milestones

Laparoscopic-assisted colonoscopy with polypectomy reduces hospital utilization

Laparoscopic-assisted colonoscopy with polypectomy reduces hospital utilization

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

Covagen begins COVA322 Phase Ib/IIa study to treat patients with rheumatoid and psoriatic arthritis

Covagen begins COVA322 Phase Ib/IIa study to treat patients with rheumatoid and psoriatic arthritis

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

UH biomedical engineer receives ALR grant to study cause of lupus nephritis

UH biomedical engineer receives ALR grant to study cause of lupus nephritis

New two-year data from Biogen Idec’s Phase 3 trial for peginterferon beta-1a presented at AAN annual meeting

New two-year data from Biogen Idec’s Phase 3 trial for peginterferon beta-1a presented at AAN annual meeting

Research provides definitive evidence of safety of Tdap immunization during pregnancy

Research provides definitive evidence of safety of Tdap immunization during pregnancy

Vibrating oral capsule for chronic constipation shows positive results

Vibrating oral capsule for chronic constipation shows positive results

Ruthigen files IND Application to FDA for lead drug candidate RUT58-60

Ruthigen files IND Application to FDA for lead drug candidate RUT58-60

New computational model rapidly assess therapy outcomes in prostate cancer patients with bone metastasis

New computational model rapidly assess therapy outcomes in prostate cancer patients with bone metastasis

UT Southwestern docs receive grants for innovative studies on lung cancer pathways, drug therapy

UT Southwestern docs receive grants for innovative studies on lung cancer pathways, drug therapy

Biotech to the rescue

Biotech to the rescue

Ranibizumab trial gets promising results for CNV

Ranibizumab trial gets promising results for CNV

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.